Redefining NAD+ Supplementation Through Science & Precision
99.9%
β-NMN Purity
98.6%
Bioavailability
5,000
Clinical Trial Subjects
Why Aiaom?
Six pillars — from raw material to absorption, from technology to clinical evidence — build our brand moat.
16 Years
Research Heritage
Dedicated cellular research with international aging laboratories and 28 international patents.
PAM4.0
Patented Absorption Technology
Dedicated cellular research with international aging laboratories and 28 international patents.
99.9%
High-Purity Ingredients
Enzyme-based synthesis with dual purification. 100% β-form, third-party verified by SGS & CNAS.
6 Formulas
Targeted Formulations
Distinct NMN and NMNH formulas for men and women, with transparent, clinically reasoned ingredient profiles.
5,000
Clinical Evidence
Randomized double-blind trials with no serious adverse events reported. Evidence over marketing.
30+
Global Compliance
EFSA-recognized safety data, FDA GMP-compliant production, and distribution in 30+ countries.
PAM4.0 Precision Activation Matrix
A three-stage synergistic system that addresses gastric degradation, absorption barriers,
and inefficient conversion.
STAGE 1 · MOLECULAR PROTECTION
Protect
50nm nano-coating shields NMN from gastric acid — stable for 2.5 hours in pH 1–3 gastric environment.
98.3% Activity Retained
STAGE 2 · TARGETED TRANSPORT
Transport
Activates intestinal Slc12a8 transporter proteins, improving cell membrane penetration and narrowing age-related absorption gaps.
+82% Membrane Penetration
STAGE 3 · CELLULAR ACTIVATION
Activate
Synergistic cofactors (PQQ, CoQ10) optimize NAD+ conversion pathways and reduce hepatic loss.
98.6% Bioavailability
Featured Products
Feugiat pretium nibh ipsum consequat commodo.
-

NMN For Basic Version
$299.00 -

NMN For Classic 32000
$359.00 -

NMN For Men 32000
$399.00 -

NMN For Women 32000
$399.00 -

NMNH For MEN
$499.00 -

NMNH For Women
$499.00
Science & Evidence
Clinical data and third-party certifications build a traceable trust system.
5,000-Person Randomized Double-Blind Trial
Conducted with international aging research institutions, tracking biomarkers over 8–12 weeks. No serious adverse events were reported.
+356%
Average NAD+ elevation in trial subjects (8 weeks, brand-claimed)
89.3%
Average NAD+ elevation in trial subjects (8 weeks, brand-claimed)
+356%
Average NAD+ elevation in trial subjects (8 weeks, brand-claimed)
89.3%
Average NAD+ elevation in trial subjects (8 weeks, brand-claimed)
Latest News
Feugiat pretium nibh ipsum consequat commodo.

What Is NMN? A Beginner’s Guide to NAD+ Precursor Supplements
As people pay more attention to long‑term cellular health, NMN…

Why Absorption Technology Matters More Than NMN Purity Alone
When shopping for NMN supplements, most consumers focus heavily on…

NMN vs NMNH: Understanding The Difference Between Two NAD+ Precursors
With the rise of reduced‑form NMNH supplements, many customers ask:…
